Hypoxia and oxidative stress in breast cancer. Hypoxia signalling pathways.


:Hypoxia-inducible factor-1 (HIF), which is centrally involved in physiological oxygen homeostasis, is also activated in the majority of tumours. Activation of HIF can occur through genetic mechanisms or as a result of hypoxia within the tumour microenvironment. In some cases HIF activation appears to be intimately linked to the proliferative stimulus itself. HIF affects patterns of gene expression and tumour growth, although precise effects vary between tumour types. Modulation of HIF activity, if correctly applied, may be therapeutically beneficial in tumour therapy.


Breast Cancer Res


Pugh CW,Gleadle J,Maxwell PH





Has Abstract


2001-01-01 00:00:00












  • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.

    abstract:BACKGROUND:We previously performed a case-control genome-wide association study in women treated with selective estrogen receptor modulators (SERMs) for breast cancer prevention and identified single nucleotide polymorphisms (SNPs) in ZNF423 as potential biomarkers for response to SERM therapy. The ZNF423rs9940645 SNP,...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Qin S,Ingle JN,Liu M,Yu J,Wickerham DL,Kubo M,Weinshilboum RM,Wang L

    更新日期:2017-08-18 00:00:00

  • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.

    abstract:BACKGROUND:The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). METHODS:Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negativ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究


    authors: O'Shaughnessy J,Brezden-Masley C,Cazzaniga M,Dalvi T,Walker G,Bennett J,Ohsumi S

    更新日期:2020-10-27 00:00:00

  • Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.

    abstract:INTRODUCTION:Menopausal hormone therapies vary widely in their effects on breast cancer risk, and the mechanisms underlying these differences are unclear. The primary goals of this study were to characterize the mammary gland transcriptional profile of estrogen + progestin therapy in comparison with estrogen-alone or t...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Wood CE,Branstetter D,Jacob AP,Cline JM,Register TC,Rohrbach K,Huang LY,Borgerink H,Dougall WC

    更新日期:2013-01-01 00:00:00

  • A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

    abstract:INTRODUCTION:There is an unmet clinical need for biomarkers to identify breast cancer patients at an increased risk of developing brain metastases. The objective is to identify gene signatures and biological pathways associated with human epidermal growth factor receptor 2-positive (HER2+) brain metastasis. METHODS:We...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: McMullin RP,Wittner BS,Yang C,Denton-Schneider BR,Hicks D,Singavarapu R,Moulis S,Lee J,Akbari MR,Narod SA,Aldape KD,Steeg PS,Ramaswamy S,Sgroi DC

    更新日期:2014-03-14 00:00:00

  • Sulfatide decreases the resistance to stress-induced apoptosis and increases P-selectin-mediated adhesion: a two-edged sword in breast cancer progression.

    abstract:BACKGROUND:We have previously shown that galactosylceramide (GalCer) affects the tumourigenic and metastatic properties of breast cancer cells by acting as an anti-apoptotic molecule. Since GalCer is a precursor molecule in the synthesis of sulfatides, the present study was aimed to define the role of sulfatides in apo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Suchanski J,Grzegrzolka J,Owczarek T,Pasikowski P,Piotrowska A,Kocbach B,Nowak A,Dziegiel P,Wojnar A,Ugorski M

    更新日期:2018-11-06 00:00:00

  • Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.

    abstract:BACKGROUND:Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. METHODS:From 32,295 female BRCA1/2 mutation carriers, w...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究


    authors: Rebbeck TR,Friebel TM,Mitra N,Wan F,Chen S,Andrulis IL,Apostolou P,Arnold N,Arun BK,Barrowdale D,Benitez J,Berger R,Berthet P,Borg A,Buys SS,Caldes T,Carter J,Chiquette J,Claes KB,Couch FJ,Cybulski C,Daly MB,d

    更新日期:2016-11-11 00:00:00

  • Polymorphic repeat in AIB1 does not alter breast cancer risk.

    abstract::STATEMENT OF FINDINGS: We assessed the association between a glutamine repeat polymorphism in AIB1 and breast cancer risk in a case-control study (464 cases, 624 controls) nested within the Nurses' Health Study cohort. We observed no association between AIB1 genotype and breast cancer incidence, or specific tumor char...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Haiman CA,Hankinson SE,Spiegelman D,Colditz GA,Willett WC,Speizer FE,Brown M,Hunter DJ

    更新日期:2000-01-01 00:00:00

  • Genomic signature of parity in the breast of premenopausal women.

    abstract:BACKGROUND:Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal wom...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Santucci-Pereira J,Zeleniuch-Jacquotte A,Afanasyeva Y,Zhong H,Slifker M,Peri S,Ross EA,López de Cicco R,Zhai Y,Nguyen T,Sheriff F,Russo IH,Su Y,Arslan AA,Bordas P,Lenner P,Åhman J,Landström Eriksson AS,Johansson R,H

    更新日期:2019-03-28 00:00:00

  • Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry.

    abstract:BACKGROUND:Approximately 100 common breast cancer susceptibility alleles have been identified in genome-wide association studies (GWAS). The utility of these variants in breast cancer risk prediction models has not been evaluated adequately in women of Asian ancestry. METHODS:We evaluated 88 breast cancer risk variant...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Wen W,Shu XO,Guo X,Cai Q,Long J,Bolla MK,Michailidou K,Dennis J,Wang Q,Gao YT,Zheng Y,Dunning AM,García-Closas M,Brennan P,Chen ST,Choi JY,Hartman M,Ito H,Lophatananon A,Matsuo K,Miao H,Muir K,Sangrajrang S,

    更新日期:2016-12-08 00:00:00

  • Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells.

    abstract:BACKGROUND:Acquirement of resistance is always associated with a highly aggressive phenotype of tumor cells. Recent studies have revealed that Annexin A2 (Anxa2) is a key protein that links drug resistance and cancer metastasis. A high level of Anxa2 in cancer tissues is correlated to a highly aggressive phenotype. Inc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Fan Y,Si W,Ji W,Wang Z,Gao Z,Tian R,Song W,Zhang H,Niu R,Zhang F

    更新日期:2019-05-22 00:00:00

  • Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

    abstract:BACKGROUND:The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer pat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Kennedy SP,Han JZR,Portman N,Nobis M,Hastings JF,Murphy KJ,Latham SL,Cadell AL,Miladinovic D,Marriott GR,O'Donnell YEI,Shearer RF,Williams JT,Munoz AG,Cox TR,Watkins DN,Saunders DN,Timpson P,Lim E,Kolch W,Croucher

    更新日期:2019-03-21 00:00:00

  • Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival.

    abstract:INTRODUCTION:Cytokeratin (CK) 14, one of several markers expressed in normal myoepithelial/basal cells, is also expressed in a proportion of breast carcinomas. Previous studies have suggested that expression of such 'basal' markers predicts different biological behaviour, with more frequent lung and brain metastases an...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Fulford LG,Reis-Filho JS,Ryder K,Jones C,Gillett CE,Hanby A,Easton D,Lakhani SR

    更新日期:2007-01-01 00:00:00

  • The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.

    abstract:BACKGROUND:Tumor hypoxia is an independent prognostic factor associated with poor patient survival. Emerging evidence suggests that hypoxia can potentially maintain or enhance the stem cell phenotype of both normal stem cells and cancer cells. However, it remains to be determined whether cell fate is regulated in vivo ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Kim H,Lin Q,Glazer PM,Yun Z

    更新日期:2018-03-06 00:00:00

  • GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells.

    abstract:INTRODUCTION:Recent studies have demonstrated that members of the GATA-binding protein (GATA) family (GATA4 and GATA5) might have pivotal roles in the transcriptional upregulation of mucin genes (MUC2, MUC3 and MUC4) in gastrointestinal epithelium. The zinc-finger GATA3 transcription factor has been reported to be invo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Abba MC,Nunez MI,Colussi AG,Croce MV,Segal-Eiras A,Aldaz CM

    更新日期:2006-01-01 00:00:00

  • A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFβ signaling in the mammary gland.

    abstract:INTRODUCTION:Molecular dissection of the signaling pathways that underlie complex biological responses in the mammary epithelium is limited by the difficulty of propagating large numbers of mouse mammary epithelial cells, and by the inability of ribonucleic acid interference (RNAi)-based knockdown approaches to fully a...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Kohn EA,Du Z,Sato M,Van Schyndle CM,Welsh MA,Yang YA,Stuelten CH,Tang B,Ju W,Bottinger EP,Wakefield LM

    更新日期:2010-01-01 00:00:00

  • Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles.

    abstract:INTRODUCTION:The presence of tumor cells in the axillary lymph nodes is the most important prognostic factor in early stage breast cancer. However, the optimal method for sentinel lymph node (SLN) examination is still sought and currently many different protocols are employed. To examine two approaches for tumor cell d...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Tveito S,Andersen K,Kåresen R,Fodstad Ø

    更新日期:2011-08-04 00:00:00

  • ALK alteration is a frequent event in aggressive breast cancers.

    abstract:INTRODUCTION:Breast cancer is the most common female malignancy worldwide and, despite improvements in treatment modalities, there are increased chances of recurrence and metastasis in a substantial number of cases and it remains one of the major causes of mortality among female cancer patients. Anaplastic lymphoma kin...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Siraj AK,Beg S,Jehan Z,Prabhakaran S,Ahmed M,R Hussain A,Al-Dayel F,Tulbah A,Ajarim D,Al-Kuraya KS

    更新日期:2015-09-17 00:00:00

  • Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.

    abstract:INTRODUCTION:Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast cancers. It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Fuentes G,Scaltriti M,Baselga J,Verma CS

    更新日期:2011-05-22 00:00:00

  • Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.

    abstract::Transforming growth factor-beta (TGF-beta) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-beta are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审


    authors: Kretzschmar M

    更新日期:2000-01-01 00:00:00

  • Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.

    abstract:BACKGROUND:Developing novel strategies against treatment-resistant triple negative breast cancer (TNBC) cells remains a significant challenge. The ErbB family, including epidermal growth factor receptor (EGFR), plays key roles in metastasis, tumorigenesis, cell proliferation, and drug resistance. Recently, these charac...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Tanei T,Choi DS,Rodriguez AA,Liang DH,Dobrolecki L,Ghosh M,Landis MD,Chang JC

    更新日期:2016-01-12 00:00:00

  • Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer.

    abstract:INTRODUCTION:The purpose of this work was to study the prognostic influence in breast cancer of thioredoxin reductase 1 (TXNRD1) and thioredoxin interacting protein (TXNIP), key players in oxidative stress control that are currently evaluated as possible therapeutic targets. METHODS:Analysis of the association of TXNR...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究


    authors: Cadenas C,Franckenstein D,Schmidt M,Gehrmann M,Hermes M,Geppert B,Schormann W,Maccoux LJ,Schug M,Schumann A,Wilhelm C,Freis E,Ickstadt K,Rahnenführer J,Baumbach JI,Sickmann A,Hengstler JG

    更新日期:2010-01-01 00:00:00

  • Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.

    abstract:INTRODUCTION:Mammary-specific overexpression of Six1 in mice induces tumors that resemble human breast cancer, some having undergone epithelial to mesenchymal transition (EMT) and exhibiting stem/progenitor cell features. Six1 overexpression in human breast cancer cells promotes EMT and metastatic dissemination. We hyp...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Iwanaga R,Wang CA,Micalizzi DS,Harrell JC,Jedlicka P,Sartorius CA,Kabos P,Farabaugh SM,Bradford AP,Ford HL

    更新日期:2012-07-05 00:00:00

  • HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer.

    abstract:BACKGROUND:Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth factor receptor 2 (HER2) expression on CTCs and tdEVs of metastatic breast cancer patients. METHODS:B...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Nanou A,Zeune LL,Bidard FC,Pierga JY,Terstappen LWMM

    更新日期:2020-08-12 00:00:00

  • The pathology of familial breast cancer: Morphological aspects.

    abstract::A small proportion of breast cancers are due to a heritable predisposition. Recently, two predisposition genes, BRCA1 and BRCA2, have been identified and cloned. The morphological features of tumours from patients harbouring mutations in the BRCA1 and BRCA2 genes differ from each other and from sporadic breast cancers...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审


    authors: Lakhani SR

    更新日期:1999-01-01 00:00:00

  • Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

    abstract:INTRODUCTION:Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable b...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Darb-Esfahani S,Loibl S,Müller BM,Roller M,Denkert C,Komor M,Schlüns K,Blohmer JU,Budczies J,Gerber B,Noske A,du Bois A,Weichert W,Jackisch C,Dietel M,Richter K,Kaufmann M,von Minckwitz G

    更新日期:2009-01-01 00:00:00

  • Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

    abstract:BACKGROUND:Fragments of collagen type I containing the epitope AHDGGR (CTX) are generated during bone resorption. The aspartyl-glycine (DG) site within CTX is synthesised in the L-aspartyl peptide (alphaL) form, but converts to the age-modified forms L-isoaspartyl peptide (betaL) and D-aspartyl peptide (alphaD) over ti...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Cloos PA,Christgau S,Lyubimova N,Body JJ,Qvist P,Christiansen C

    更新日期:2003-01-01 00:00:00

  • Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

    abstract::Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Rossi L,Biagioni C,McCartney A,Migliaccio I,Curigliano G,Sanna G,Moretti E,Minisini AM,Cinieri S,Tondini C,Arpino G,Bernardo A,Martignetti A,Risi E,Pestrin M,Boni L,Benelli M,Biganzoli L,Di Leo A,Malorni L

    更新日期:2019-05-29 00:00:00

  • Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.

    abstract:INTRODUCTION:Aberrant expression of the embryonic stem cell marker Sox2 has been reported in breast cancer (BC). We previously identified two phenotypically distinct BC cell subsets separated based on their differential response to a Sox2 transcription activity reporter, namely the reporter-unresponsive (RU) and the mo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Jung K,Wang P,Gupta N,Gopal K,Wu F,Ye X,Alshareef A,Bigras G,McMullen TP,Abdulkarim BS,Lai R

    更新日期:2014-11-08 00:00:00

  • Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

    abstract::Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these p...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章


    authors: Schneider BP,Sledge GW Jr

    更新日期:2009-01-01 00:00:00

  • Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.

    abstract::Adjuvant hormonal therapy for postmenopausal women with early stage breast cancer has become far more complex over the past several years. This commentary reviews the current status of the five major trials evaluating the use of the aromatase inhibitors in the adjuvant setting. The data currently available suggest tha...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审


    authors: Ligibel JA,Winer EP

    更新日期:2005-01-01 00:00:00